LUM-201 Market Summary

Key Factors Driving LUM-201 Growth

1. Potential to become the first oral treatment for pediatric GHD: LUM-201 is an orally administered growth hormone secretagogue receptor (GHSR) agonist that stimulates endogenous GH release and increases the amplitude of natural pulsatile GH secretion. This differentiates it from injectable recombinant human GH therapies. If approved, it could address a major treatment burden associated with repeated injections in children requiring long-term therapy. Lumos currently describes its Phase III program as evaluating LUM-201 in children with pediatric GHD (PGHD).

2. Promising Phase II growth efficacy: The Phase II OraGrowtH210 study generated encouraging efficacy data. At the selected 1.6 mg/kg/day dose, LUM-201 produced an annualized height velocity (AHV) of 8.2 cm/year at 6 months and 7.6–8.0 cm/year at 12 months, compared with a baseline AHV of approximately 4.7 cm/year. The company reported that the treatment effect remained durable through 24 months, with AHV of 8.1 cm/year at 12 months and 7.3 cm/year at 24 months in the per-protocol population. These results provide the clinical foundation for advancing LUM-201 into pivotal development.

3. Predictive-enrichment strategy could improve clinical and commercial positioning: LUM-201 is being developed with a predictive enrichment marker (PEM) approach designed to identify children most likely to respond. Published analysis of 68 treatment-naïve, prepubertal children identified two markers—baseline IGF-1 >30 ng/mL and a peak GH response ≥5 ng/mL following a single LUM-201 dose—that together enriched for patients expected to respond better to LUM-201. This could enable more targeted patient selection, potentially improving the benefit-risk profile and probability of clinical success.

4. Physiological, pulsatile GH mechanism may offer a differentiated treatment profile: Unlike exogenous GH injections, LUM-201 stimulates the patient's own pituitary to release GH. In the Phase II OraGrowtH212 PK/PD study, Lumos reported that LUM-201 achieved expected growth while producing approximately 20% of the GH exposure/concentration associated with injectable rhGH and maintained a more physiological pulsatile secretion pattern. In the earlier 68-patient analysis, a single LUM-201 dose produced a median GH response of 15.0 ng/mL versus 5.5 ng/mL with standard diagnostic stimulation tests (p<0.0001). These findings support LUM-201's differentiated pharmacological profile.

5. Large convenience advantage versus injectable GH: Even though newer weekly GH products such as SOGROYA, SKYTROFA and NGENLA have reduced injection frequency, LUM-201 could potentially go a step further by offering daily oral administration rather than injections altogether. Lumos has developed a compactable formulation containing mini-tablets intended to reduce dose variability and facilitate administration in younger children. The company received USPTO patent protection for this formulation in 2024, extending reported protection for the improved formulation to November 2042.

6. Phase III development and potential expansion beyond PGHD create future upside: The current global Phase III OraGrowtH study is a 12-month, randomized, double-blind, placebo-controlled study expected to enroll approximately 150 prepubertal children and is designed both to evaluate efficacy/safety and validate the PEM strategy. The trial is currently listed as recruiting. Lumos' development plans also identify potential future opportunities in idiopathic short stature (ISS), small for gestational age (SGA), and cardiometabolic indications, although these remain investigational and should not be treated as established revenue opportunities.

LUM-201 Recent Developments

In December 2024, Lumos Pharma, Inc. (“Lumos Pharma” or the “Company”), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, and Double Point Ventures LLC (“DPV”) today announced the successful completion of the previously announced tender offer for Lumos Pharma’s shares at a purchase price of (i) $4.25 per share in cash at closing, without interest and less applicable tax withholding and (ii) one contingent value right (“CVR”) for each share of common stock outstanding, representing the future right to receive additional contingent cash payments upon the achievement of certain milestone events relating to the level of annual global net revenue of LUM-201 up to the year 2037, different transactions involving Lumos Pharma or its assets that occur within 18 months of closing or certain sales, license or similar revenue-generating agreements entered into within 18 months of closing and that are related to Lumos Pharma’s legacy products other than LUM-201.

“LUM-201 Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of LUM-201 for potential indication like Somatotropin deficiency, Non-alcoholic fatty liver disease, and Obesity in the 7MM. A detailed picture of LUM-201’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the LUM-201 for potential indications. The LUM-201 market report provides insights about LUM-201’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current LUM-201 performance, future market assessments inclusive of the LUM-201 market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of LUM-201 sales forecasts, along with factors driving its market.

LUM-201 Drug Summary

LUM-201 (Ibutamoren) is an investigational, orally administered growth hormone (GH) secretagogue developed by Lumos Pharma for the treatment of growth hormone deficiency (GHD), particularly in pediatric patients. Unlike recombinant human growth hormone therapies that require injections, LUM-201 is designed as a once-daily oral therapy that stimulates the body’s endogenous secretion of growth hormone by acting as an agonist of the ghrelin receptor (growth hormone secretagogue receptor, GHSR-1a) in the hypothalamus and pituitary gland. This mechanism promotes pulsatile release of endogenous GH, which subsequently increases circulating insulin-like growth factor-1 (IGF-1) and supports growth and development. LUM-201 is being investigated primarily in children with GHD who have demonstrated sufficient GH reserve or specific biomarkers predictive of response, with clinical development focusing on identifying patients most likely to benefit from oral GH stimulation. The drug is being evaluated as a potential alternative to daily injectable recombinant GH, with the potential advantages of oral administration, reduced treatment burden, and stimulation of physiological pulsatile GH secretion. As an investigational therapy, LUM-201 is not approved for routine clinical use and continues to require clinical validation regarding long-term efficacy, safety, appropriate patient selection, and its ability to achieve growth outcomes comparable with established injectable GH treatments. The report provides LUM-201’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the LUM-201 Market Report

The report provides insights into:

• A comprehensive product overview including the LUM-201 MoA, description, dosage and administration, research and development activities in potential indication like Somatotropin deficiency, Non-alcoholic fatty liver disease, and Obesity.
• Elaborated details on LUM-201 regulatory milestones and other development activities have been provided in LUM-201 market report.
• The report also highlights LUM-201‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The LUM-201 market report also covers the patents information, generic entry and impact on cost cut.
• The LUM-201 market report contains current and forecasted LUM-201 sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The LUM-201 market report also features the SWOT analysis with analyst views for LUM-201 in potential indications.

Methodology

The LUM-201 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

LUM-201 Analytical Perspective by DelveInsight

• In-depth LUM-201 Market Assessment

This LUM-201 sales market forecast report provides a detailed market assessment of LUM-201 for potential indication like Somatotropin deficiency, Non-alcoholic fatty liver disease, and Obesity in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted LUM-201 sales data uptil 2034.

• LUM-201 Clinical Assessment

The LUM-201 market report provides the clinical trials information of LUM-201 for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

LUM-201 Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

LUM-201 Market Potential & Revenue Forecast

• Projected market size for the LUM-201 and its key indications
• Estimated LUM-201 sales potential (LUM-201 peak sales forecasts)
• LUM-201 Pricing strategies and reimbursement landscape

LUM-201 Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• LUM-201 Market positioning compared to existing treatments
• LUM-201 Strengths & weaknesses relative to competitors

LUM-201 Regulatory & Commercial Milestones

• LUM-201 Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

LUM-201 Clinical Differentiation

• LUM-201 Efficacy & safety advantages over existing drugs
• LUM-201 Unique selling points

LUM-201 Market Report Highlights

• In the coming years, the LUM-201 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The LUM-201 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence LUM-201’s dominance.
• Other emerging products for Somatotropin deficiency, Non-alcoholic fatty liver disease, and Obesity are expected to give tough market competition to LUM-201 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of LUM-201 in potential indications.
• Analyse LUM-201 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted LUM-201 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of LUM-201 in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of LUM-201? How strong is LUM-201’s clinical and commercial performance?
• What is LUM-201’s clinical trial status in each individual indications such as Somatotropin deficiency, Non-alcoholic fatty liver disease, and Obesity and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the LUM-201 Manufacturers?
• What are the key designations that have been granted to LUM-201 for potential indications? How are they going to impact LUM-201’s penetration in various geographies?
• What is the current and forecasted LUM-201 market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of LUM-201 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to LUM-201 for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is LUM-201? What is the duration of therapy and what are the geographical variations in cost per patient?